HK1028546A1 - Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders - Google Patents

Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders

Info

Publication number
HK1028546A1
HK1028546A1 HK00106844A HK00106844A HK1028546A1 HK 1028546 A1 HK1028546 A1 HK 1028546A1 HK 00106844 A HK00106844 A HK 00106844A HK 00106844 A HK00106844 A HK 00106844A HK 1028546 A1 HK1028546 A1 HK 1028546A1
Authority
HK
Hong Kong
Prior art keywords
deficit
attention
treatment
carnitine derivatives
alkanoyl
Prior art date
Application number
HK00106844A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of HK1028546A1 publication Critical patent/HK1028546A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK00106844A 1997-07-22 2000-10-26 Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders HK1028546A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/898,433 US5869528A (en) 1997-07-22 1997-07-22 Therapeutical method for the treatment of attention-deficit/hyperactive disorders
PCT/IT1998/000188 WO1999004785A1 (en) 1997-07-22 1998-07-08 Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders

Publications (1)

Publication Number Publication Date
HK1028546A1 true HK1028546A1 (en) 2001-02-23

Family

ID=25409451

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00106844A HK1028546A1 (en) 1997-07-22 2000-10-26 Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders

Country Status (13)

Country Link
US (1) US5869528A (ja)
EP (1) EP0998276B1 (ja)
JP (1) JP4276779B2 (ja)
KR (1) KR100530879B1 (ja)
AT (1) ATE290376T1 (ja)
AU (1) AU735697B2 (ja)
CA (1) CA2297153C (ja)
DE (1) DE69829290T2 (ja)
ES (1) ES2237842T3 (ja)
HK (1) HK1028546A1 (ja)
NZ (1) NZ501966A (ja)
PT (1) PT998276E (ja)
WO (1) WO1999004785A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
SI0951909T2 (sl) 1998-03-19 2010-11-30 Sigma Tau Ind Farmaceuti Kombinirana zmes ki vsebuje L karnitin ali alkanoil L karnitin glikozaminoglikan in ali njegov sestavni del
PL345113A1 (en) 1998-06-26 2001-12-03 Iams Co Process and product for promoting weight loss in overweight dogs
US6630159B2 (en) * 1999-02-23 2003-10-07 The Procter & Gamble Company Limiting weight gain of cats by feeding carbohydrate source that excludes rice
US7001618B1 (en) 1999-07-09 2006-02-21 The Iams Company Nutritional composition for weight management
WO2001028554A1 (en) * 1999-10-20 2001-04-26 Thomas Jefferson University Treatment of attention deficit disorder and impaired visual-spatial function with androgen
ITRM20010218A1 (it) * 2001-04-23 2002-10-23 Sigma Tau Healthscience Spa Composizione per la prevenzione o il trattamento dei disturbi dell'apprendimento in bambini affetti da deficit dell'attenzione ed iperattivi
JP4812968B2 (ja) * 2001-06-06 2011-11-09 太陽化学株式会社 注意欠陥多動性障害改善用組成物
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2016130981A1 (en) 2015-02-13 2016-08-18 Mars, Incorporated Pet food feeding system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism

Also Published As

Publication number Publication date
ES2237842T3 (es) 2005-08-01
EP0998276A1 (en) 2000-05-10
DE69829290T2 (de) 2006-04-13
KR20010022008A (ko) 2001-03-15
EP0998276B1 (en) 2005-03-09
US5869528A (en) 1999-02-09
ATE290376T1 (de) 2005-03-15
NZ501966A (en) 2001-12-21
PT998276E (pt) 2005-06-30
JP4276779B2 (ja) 2009-06-10
CA2297153A1 (en) 1999-02-04
AU735697B2 (en) 2001-07-12
DE69829290D1 (de) 2005-04-14
AU8240598A (en) 1999-02-16
CA2297153C (en) 2007-07-03
WO1999004785A1 (en) 1999-02-04
KR100530879B1 (ko) 2005-11-23
JP2001510800A (ja) 2001-08-07

Similar Documents

Publication Publication Date Title
EP0787489A3 (ja)
HUS1300046I1 (hu) Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására
HK1028546A1 (en) Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
ZA963826B (en) A method of treatment of mania and bipolar disorder
GR3032903T3 (en) Medicament containing a carnitine derivative for treating arteriosclerosis obliterans
ZA948927B (en) Melatonin derivatives for use in treating sleep disorders
AU670491C (en) Pharmaceutical for the treatment of skin disorders
HU9302389D0 (en) Stable salts of (+)-(1s,2r)-2-(/n-(2-hydroxi-amino-2-oxo-ethyl)-n-metnhyl-amino/-carbonyl/cyclohexane-1-carboxylic acid and method for producing them
SI0998276T1 (en) Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
IT1299069B1 (it) Composizione farmaceutica per il trattamento della "sindrome dolorosa regionale cronica" ("chronic regional pain syndrome crps")
TW362972B (en) Use of lower alkanoyl L-carnitines to produce a medicament suitable for the therapeutic treatment of retinopathies
MX9709299A (es) Uso de las l-carnitinas de alcanoilo inferior para producir un medicamento apropiado para el tratamiento terapeutico de retinopatias.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120708